Effects of bolesatine on a cell line from the SP2/O thymic lymphosarcoma.
Bolesatine, a toxic protein isolated from Boletus satanas Lenz inhibits in vitro protein synthesis in a concentration-dependent manner in a cell line from a radiation-induced thymic lymphosarcoma (SP2/O) with a 50% inhibitory concentration (IC50) of 9.5 nM (0.6 microgram/ml). In vivo, an i.p. single injection of bolesatine, corresponding to 1/6 and 1/10 of 24-h 50% lethal dose, in Balb/c mice having ascitic tumour induced by the i.p. preinjection of SP2/O cells allows a remission of 50% and 30%, respectively. Treated mice survived 120 days after the treatment, i.e. 90 days after the death of control animals.
Basset
L
L
University of Bordeaux 2, Faculty of Pharmaceutical Sciences, Laboratory of Toxicology and Applied Hygiene, France.
Ennamany
R
R
Portail
J P
JP
Kretz
O
O
Deffieux
G
G
Badoc
A
A
Guillemain
B
B
Creppy
E E
EE
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005656:Fungal Proteins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007700:Kinetics; D007928:Lethal Dose 50; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009183:Mycotoxins; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000401:mortality; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use / Q000633:toxicity*; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D005656:Fungal Proteins; D009183:Mycotoxins; D011500:Protein Synthesis Inhibitors; C060924:Bolesatine protein, Boletus satanas